Off‐Label Use of Mycophenolate: Can Real‐World Evidence Fetch Regulatory Approval for Lupus Nephritis and Other Indications?

Ähnliche Einträge

• Reply to: “Current Use of PBPK Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis”
  von: Polly Paul, et al.
  Veröffentlicht: (2025)
• The Use of Real‐World Evidence for Regulatory Decisions in China
  von: Jiayue Xu, et al.
  Veröffentlicht: (2024)
• Real‐World Evidence in Regulatory Decision Making: Time for Evidence Integration
  von: Rebecca A. Miksad
  Veröffentlicht: (2024)
• The Open Hand Initiative: Facilitating the Use of Real‐World Evidence in Regulatory Submissions Through Collaboration and Transparency
  von: Elodie Baumfeld Andre, et al.
  Veröffentlicht: (2024)
• Clinical Benefit, Trials, and Regulatory Approval of Oncology Indications Under Multiple Expedited Programs for Drug Marketing in China, 2018–2024
  von: Jie Zhang, et al.
  Veröffentlicht: (2025)